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ABSTRACT
The clinical significance of Cluster of Differentiation 44 (CD44) remains 
controversial in human ovarian cancer. The aim of this study is to evaluate the 
clinical significance of CD44 expression by using a unique tissue microarray, and 
then to determine the biological functions of CD44 in ovarian cancer. In this study, a 
unique ovarian cancer tissue microarray (TMA) was constructed with paired primary, 
metastatic, and recurrent tumor tissues from 26 individual patients. CD44 expression 
in TMA was assessed by immunohistochemistry. Both the metastatic and recurrent 
ovarian cancer tissues expressed higher level of CD44 than the patient-matched 
primary tumor. A significant association has been shown between CD44 expression 
and both the disease free survival and overall survival. A strong increase of CD44 was 
found in the tumor recurrence of mouse model. Finally, when CD44 was knocked down, 
proliferation, migration/invasion activity, and spheroid formation were significantly 
suppressed, while drug sensitivity was enhanced. Thus, up-regulation of CD44 
represents a crucial event in the development of metastasis, recurrence, and drug 
resistance to current treatments in ovarian cancer. Developing strategies to target 
CD44 may prevent metastasis, recurrence, and drug resistance in ovarian cancer.
INTRODUCTION
Epithelium ovarian carcinoma ranks fifth in lethal 
tumors among women, accounting for more deaths than 
any other cancer of the female genital tract. Based on the 
estimation of ovarian cancer for 2014 by the American 
Cancer Society, approximately 21,980 women will receive 
a new diagnosis of ovarian cancer, and near 14,270 
women will succumb to this disease in the United States 
[1]. Conventional combinations of primary cytoreductive 
surgery and paclitaxel-platinum chemotherapy have not 
had a significant impact on overall survival of ovarian 
cancer in last several decades [2, 3]. The overall five-year 
survival rates of patients diagnosed at stage III and IV 
of this disease is 32% and 18%, respectively [4]. Most 
ovarian cancer patients who were initially responsive 
to standard chemotherapeutic regimens will inevitably 
relapse with metastasis, recurrence, and drug resistance. 
However, the mechanisms of development of relapsed 
ovarian cancer are still largely unknown.
Cluster of Differentiation 44 (CD44) is a polymorphic 
group of proteins, mainly owing to alternatively spliced 
exon transcripts in the extracellular domains [5]. The 
heterogeneity of the protein products vary on different cell 
types and growth conditions (all termed as CD44 in this 
study). The smallest CD44 isoform, which is also known 
as standard or haematopoietic isoform, is ubiquitously 
expressed on the membrane of most vertebrate cells 
[6], while other larger CD44 splice variants are merely 
present on limited types of epithelial tissue [7]. The CD44 
transmembrane glycoprotein family mediates diverse 
cellular processes, which involve the regulation of growth, 
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survival, differentiation, and motility. Despite CD44 
is frequently expressed in a wide variety of epithelial 
malignancies, including ovarian cancer. However, the 
clinical significance of CD44 remains controversial. Some 
studies have concluded that an association between CD44 
expression and poor prognosis or survival outcome [8, 9], 
whereas other studies did not demonstrate any correlations 
of these two factors [10, 11]. Few studies have investigated 
CD44 expression in ovarian cancer patients with long-term 
follow up. No previous CD44 studies have been carried 
out with paired primary, metastatic, and recurrent tumor 
tissues from each individual ovarian cancer patient. Most 
importantly, the effect of chemotherapy treatment on CD44 
expression in ovarian cancer is also unknown. The aim of 
this study is to further investigate and clarify expression and 
function of CD44 in ovarian cancer.
RESULTS
Unique features of the constructed human 
ovarian cancer TMA
In previous studies, most reports used a TMA 
either from different disease stages or from various 
histopathological types in large patient cohort [12–15]. 
The TMA utilized in our current study was generated from 
26 well-characterized late-stage ovarian cancer patients 
with long-term follow-up (Supplementary Table S1). The 
unique features of our TMA are that tissues are collected 
from paired primary, metastatic, and recurrent tumor tissues 
each from 26 individual patients. To our knowledge, no such 
human ovarian cancer tumor TMA has been constructed 
in former reports. Most patients were grade 3 at time of 
diagnosis, while there were four grade 2 patients and one 
grade 1 patient. All the patients were disease stage III 
to IV with various pathological types, including serous, 
transitional cell, endometroid, clear cell, undifferentiated 
cell, etc. The time range of DFS was between 5.3 months 
and 53.3 months; the shortest OS of a patient was 12 months, 
and the longest follow-up of a living patient is 162.3 months.
Increased expression of CD44 in metastatic and 
recurrent ovarian cancer tissues, and correlated 
with poor clinical outcome
Almost all of the tumor specimens presented various 
degrees of CD44 expression on the cell membrane (Figure 1 
Panel B). Although no remarkable differences of the 
overall mean CD44 immunostaining scores were observed 
between patient-matched metastasis and recurrent ovarian 
cancer tumors, the expression level of CD44 was lower 
in primary ovarian cancer tissue than in synchronous 
metastasis and recurrence, with a significant difference 
of approximately 0.6 in staining intensity (P value of 
metastatic vs. primary = 0.034; P value of recurrent vs. 
primary = 0.037; Figure 1 Panel A). In order to clarify the 
initial immunohistochemistry results, follow-up analysis 
were performed to analyze the association of CD44 
expression and ovarian cancer progression and prognosis. 
Patients were sorted according to CD44 expression 
score (weak CD44 staining score ranging from 0 to 1+, 
and strong CD44 staining score ranging from 2+ to 3+). 
A significant tendency of CD44 overexpression towards 
unfavorable prognosis was displayed in analysis of both 
overall survival and disease free survival, with P values 
at 0.010 and 0.036, respectively (Figure 1 Panel C and D).
CD44 is overexpressed in drug resistant ovarian 
cancer cell lines
Late-stage ovarian cancer exhibits more aggressive 
tumor progression, especially resistant to conventional 
chemotherapeutic drugs. Based on the results of CD44 
immunostaining in our TMA, we further examined 
the relative expression levels of CD44 in two pairs of 
well-characterized drug sensitive and resistant ovarian 
cancer cell lines-SKOV-3/SKOV-3TR and OVCAR8/
OVCAR8TR. The western blot results demonstrated 
that only SKOV-3TR and OVCAR8TR exhibited strong 
expression of P-glycoprotein (Pgp), however both the 
drug sensitive and drug resistant cell lines presented a 
ubiquitous level of CD44 expression. Moreover, SKOV-
3TR and OVCAR8TR expressed significantly higher 
levels of CD44 than parental sensitive cell lines (Figure 2 
Panel A and B).
Overexpression of CD44 in the tumor recurrence 
of human ovarian cancer xenograft model 
during paclitaxel treatment
Paclitaxel is the first-line chemotherapy drug in the 
treatment of ovarian cancer. However, little is known about 
the alteration of CD44 expression in recurrent ovarian 
cancer during chemotherapy. After an ovarian cancer 
xenograft model was established, the mice were treated 
with different regimes of paclitaxel and tumor tissues 
were harvested at different stages (Figure 2 Panel C). 
The ovarian-tumor-bearing nude mice dosed with 25 mg/
kg paclitaxel were euthanized after two months, while 
tumor tissues from mice treated with saline, paclitaxel 
(10 mg/kg and 20 mg/kg) were collected after one month 
due to large tumor volume (exceeding 1000 mm3). To 
investigate the dynamic variations of CD44 in vivo, the 
relative protein level of CD44 was detected and analyzed 
by western blot and densitometry. No significant difference 
was observed between low-dosage (10 mg/kg) paclitaxel 
treated nude mice and saline treated ones; however, there 
is a slight increase of CD44 in 20 mg/kg paclitaxel treated 
mice, and dramatic overexpression of CD44 in mice dosed 
with 25 mg/kg paclitaxel. These results indicated that the 
expression of CD44 will increase in the tumor recurrence 
of ovarian cancer (Figure 2 Panel D and E).
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Knockdown of CD44 by shRNA induced the 
retardation of cell growth and inhibited the 
spheroid formation in 3-D culture of ovarian 
cancer cells
As indicated in the western blot results, OVCAR8 
expresses CD44. In order to investigate the biology of 
CD44 in ovarian cancer, we stably transduced ovarian 
cancer OVCAR8 cells by a lentivirus-mediated gene 
transfer system expressing CD44 shRNA. The controls 
were the cells without any treatments and the cells 
transfected with an empty vector or lentivirus-based 
non-specific shRNA. During the treatment period, it was 
observed that nearly all the untreated OVCAR8 cells 
were killed by 2 μg/ml puromycin on Day 5, whereas 
there was prominent cell survival in empty vector and 
lentivirus-based non-specific shRNA treated wells, and 
half the cells transduced with lentivirus-based CD44 
shRNA were still alive (Figure 3 Panel B). We then 
selected and sub-cultured the remaining viable cells in 
all the microplate wells, except for the blank control 
wells. Total protein was extracted to verify transduction 
efficiency; protein of OVCAR8 cells cultured in regular 
medium without any treatment was used as the control. 
As expected, no any alterations of CD44 were presented 
in OVCAR8Lentivirus only and OVCAR8Non-specific shRNA cells in 
comparison with the control, whereas the protein level 
of CD44 was remarkably suppressed in OVCAR8CD44 
shRNA cells. Moreover, none of the cell lines presented 
the expression of Pgp (Figure 3 Panel C). Hence, all 
the three cell lines (OVCAR8Lentivirus only, OVCAR8Non-
specific shRNA, and OVCAR8CD44 shRNA) were successfully 
established and well characterized. Next, proliferation 
of the aforementioned four cell lines was assessed 
by MTT assay. There was obvious growth inhibition 
in OVCAR8CD44 shRNA and no significant difference in 
cell growth among other control cell lines (OVCAR8, 
OVCAR8Lentivirus only, and OVCAR8Non-specific shRNA) (Figure 
3 Panel D). Furthermore, after 7-day culture in 3-D 
environment, which mimics in vivo settings, the diameter 
of spheroids formed by OVCAR8CD44 shRNA was relatively 
smaller than other cell spheroids (Figure 3 Panel E and F). 
These results suggested that CD44 enhances the 
development and progression of ovarian cancer cells.
Figure 1: Expression of CD44 and clinical significance in primary, metastatic, and recurrent ovarian cancer. Panel (A) 
distribution of CD44 immunohistochemical staining scores in primary, metastatic, and recurrent ovarian cancer. Panel (B) representative 
expression of CD44 in matched primary, metastatic, and recurrent ovarian cancers. Panel (C and D) correlation between expression of CD44 
(CD44 staining ≤ 1+ and CD44 staining ≥ 2+) and disease free survival (Panel C) or overall survival (Panel D) in ovarian cancer patients.
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Knockdown of CD44 by shRNA increased the 
drug sensitivity in ovarian cancer cells
To examine whether repression of CD44 levels 
would increase the drug sensitivity of ovarian cancer 
cells, the MTT assay was performed on the established 
cell lines OVCAR8Lentivirus only, OVCAR8Non-specific shRNA, 
and OVCAR8CD44 shRNA after incubating with paclitaxel. 
OVCAR8 cells without any treatment were used as the 
control. The representative pictures of different cells dosed 
with 0 μM paclitaxel and 0.006 μM paclitaxel were shown 
in Figure 4 Panel A. The results showed minimal survival 
of OVCAR8CD44 shRNA in medium containing 0.006 μM 
paclitaxel, while a substantial number of OVCAR8, 
OVCAR8Lentivirus only, and OVCAR8Non-specific shRNA cells were 
still able to tolerate this level of paclitaxel exposure. Further 
analysis of the MTT data indicated that knockdown of CD44 
significantly restored the sensitivity to chemotherapeutic 
drug paclitaxel in OVCAR8 (Figure 4 Panel B).
Knockdown of CD44 by esiRNA in ovarian 
cancer cells
Drug resistant ovarian cancer is more intractable 
in the clinical environment. CD44 is overexpressed in 
drug resistant ovarian cancer cell lines (Figure 2 Panel 
A and B); therefore, we examined whether disruption of 
CD44 expression would influence the function of SKOV-
3TR and OVCAR8TR. Western blot was conducted to 
detect the efficacy of CD44 esiRNA transfection in vitro. 
It was found that CD44 esiRNA transfected cells showed 
significantly reduced protein levels of CD44, compared 
with untreated cells and cells dosed with non-specific 
siRNA (Figure 5 Panel A). Moreover, the level of CD44 
expression was suppressed by CD44 targeted esiRNA in 
a dose dependent manner, as determined by densitometry 
quantification. Specifically, when normalized to untreated 
cells, the expression levels of CD44 in cells transfected 
with 18 nM, 36 nM and 54 nM CD44 esiRNA were 
Figure 2: CD44 is overexpressed in drug resistant ovarian cancer cell lines, along with the appearance of tumor 
recurrence in ovarian cancer xenograft models. Panel (A and B) relative expression levels of CD44 and Pgp in drug resistant 
cell lines SKOV-3TR, OVCAR8TR, and parental sensitive cell lines SKOV-3, OVCAR8 were determined by western blot. The assay was 
conducted in triplicate. Panel (C) schematic of human ovarian cancer xenograft establishment and paclitaxel treatment, each group has six 
female nude mice. Panel (D) relative CD44 protein levels in tumors of human ovarian cancer xenograft model treated with different doses 
of paclitaxel evaluated by western blot, which was performed in triplicate. Panel (E) a semi-quantitative analysis of relative CD44 protein 
expression determined by western bolt.
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decreased to 53.3%, 29.2%, and 18.3% for SKOV-3TR, 
and 48.7%, 29.2%, and 13.1% for OVCA8TR. However, 
knocking down of CD44 has no significant influence on 
Pgp expression (Figure 5 Panel B). In addition, results 
from the immunofluorescence study further showed that 
CD44 were effectively inhibited by 54 nM CD44 esiRNA 
in both SKOV-3TR (Figure 5 Panel C) and OVCAR8TR 
(Figure 5 Panel D) cells. Red color represents CD44 
protein and blue color represents cell nuclei.
Knockdown of CD44 by esiRNA suppressed 
the mobility and invasion activity of ovarian 
cancer cells
Migration and invasion are crucial prerequisites 
for ovarian cancer metastasis and recurrence. After 
the confirmation of remarkable knockdown of CD44 
by esiRNA in SKOV-3TR and OVCAR8TR, we next 
evaluated whether CD44 participates in the modulation 
of cell mobility. As observed in the wound healing assay, 
wounds were almost recovered after 24-hour migration 
in blank control and non-specific siRNA treated cells. 
However, the wound healing showed a substantial 
inhibition when the cells were subjected to CD44 
esiRNA, especially at higher concentrations. During 
the 24-hour incubation, the relative migratory distances 
of SKOV-3TR cells transfected with 36 nM and 54 
nM CD44 esiRNA were 32.67 mm and 22.15 mm, 
respectively; the OVCAR8TR cells dosed with 36 
nM and 54 nM CD44 esiRNA migrated merely 61.54 
mm and 45.19 mm (Figure 6 Panel A and B). To 
assess whether the invasive potential of drug resistant 
ovarian cancer cells changed in vitro when lacking 
CD44, transwell invasion assays were carried out after 
transfection using different concentrations of CD44 
esiRNA. The average numbers of CD44 esiRNA (36 nM 
and 54 nM) treated OVCAR8TR cells invading through 
the matrigel were significantly lower in contrast 
with the blank control and the non-specific siRNA 
groups (Figure 6 Panel C and D). Taken together, 
Figure 3: CD44 shRNA transduction suppressed sphere formation of OVCAR8 in three-dimensional culture. Panel (A) 
schedule of establishing OVCAR8Lentivirus only, OVCAR8Non-specific shRNA, and OVCAR8CD44 shRNA cell lines. Panel (B) status of cells that were 
successfully transduced with lentivirus and survived puromycin selection. Panel (C) western blot showing relative protein expression of 
CD44 and Pgp in established OVCAR8Lentivirus only, OVCAR8Non-specific shRNA, and OVCAR8CD44 shRNA cell lines. This assay was performed in 
triplicate. Panel (D) proliferation conditions of established OVCAR8Lentivirus only, OVCAR8Non-specific shRNA, and OVCAR8CD44 shRNA cell lines. 
The MTT assay was conducted in triplicate. (E and F) spheroids formation of different cells after 7-day culture and the relative diameters 
compared with untreated cells. The assay was conducted in duplicate.
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wound healing and transwell invasion assays both 
demonstrated that down regulation of CD44 inhibited 
the migration and invasion capabilities of SKOV-3TR 
and OVCAR8TR cells.
DISCUSSION
In the current study, we provided a comprehensive 
overall expression profile of CD44 in ovarian cancer, 
from individual patients’ clinical primary tumor tissue 
to metastasis and recurrence, and from tumor cell lines 
to xenograft mouse model. Our study demonstrated that 
both the metastatic and recurrent ovarian cancer tissues 
expressed higher levels of CD44 than patient-matched 
primary tumor samples. A pronounced association 
between the expression of CD44 and disease-specific 
survival and overall survival was observed through TMA 
immunohistochemistry analysis. When CD44 was stably 
inhibited by its specific shRNA, the proliferation speed 
and spheroids formation of ovarian cancer cells was 
inhibited under 3-D culture conditions. We also found that 
knocking down CD44 impaired the migratory and invasive 
functions. In addition, CD44 knockdown ovarian cancer 
cells increased sensitivity to the anticancer drug paclitaxel. 
Results from drug sensitive and resistant cell lines and 
from xenograft mouse model of ovarian cancer indicated 
that up-regulation of CD44 is a critical event during the 
progression of ovarian cancer.
The development of TMA technology introduces 
a cost-effective and efficient technique in conducting 
research. A large number of tumor samples can be processed 
simultaneously under uniform immunohistochemical 
experimental conditions [16]. This platform has facilitated 
evaluating the correlations between molecular variations 
and clinicopathological characteristics of tumors in a vast 
number of publications so far, including ovarian cancer. 
Various human ovarian cancer TMAs have been constructed 
in previous investigations. For instance, TMAs containing: 
136 cases of epithelial ovarian carcinoma (108 high-grade 
serous carcinoma and 28 clear cell carcinoma) [12]; a larger 
patient cohort (serous 357, endometrioid 37, mucinous 88, 
clear cell 14, etc.) [13]; 144 formaldehyde fixed-paraffin 
embedded primary ovarian tumors (grade 1 to 3, FIGO 
stage I to IV) [14]; and 99 primary epithelial ovarian 
Figure 4: Knockdown of CD44 by lentiviral shRNA increased the paclitaxel sensitivity of ovarian cancer cells.  
Panel (A) status of OVCAR8, OVCAR8Lentivirus only, OVCAR8Non-specific shRNA, and OVCAR8CD44 shRNA cells that differed between representative 
concentrations of paclitaxel (0 μM and 0.006 μM). Panel (B) MTT assay showing cell viability of the above mention four cell lines with 
different concentrations of paclitaxel. The MTT assay was conducted in triplicate.
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cancers, 22 peritoneal metastasis, and 13 normal ovarian 
samples [15]. To the best of our knowledge, no former 
studies have utilized the tumor TMA as what we used in 
this study, which was generated by 26 well characterized 
late-stage ovarian cancer patients with long-term follow-
up. The particularly remarkable feature of this TMA is that 
each patient possessed a primary tumor, a synchronous 
metastasis, and a metachronous recurrence obtained at 
the time of tumor progression after initial surgery and 
specific platinum- and/or paclitaxel-based chemotherapy. 
The metastatic and recurrent tumor sites disseminated a 
wide spectrum of organs, such as ovary, sigmoid, liver, 
brain, omentum, etc. Epithelial ovarian cancers are a 
particularly heterogeneous type of tumor, in part due to 
their large size and different histological subtypes [17, 18]. 
In this regard, three core biopsies from morphologically 
representative areas of each paraffin-embedded tumor 
tissue block were identified and collected to minimize the 
variability. Moreover, it is worth mentioning that we have 
previously applied this TMA to prove the hypothesis that 
expression of pStat3 and inflammatory infiltration increased 
in recurrent and metastatic ovarian cancer tissues [19]. 
Despite the limited numbers of cases, the results deriving 
from this unique human TMA will provide more valuable 
information.
As a multifaceted and multifunctional molecule, 
CD44 has attracted substantial interest since its first 
description [20]. CD44 is known to regulate several 
essential cellular and molecular events, including 
organ development, neuronal axon guidance, numerous 
immune functions, haematopoiesis, and pathological 
processes [21–23]. Induction of CD44 expression has 
been addressed during the progression of ovarian cancer. 
However, the role of CD44 expression in epithelial ovarian 
cancer has not been clarified and the clinical significance 
of CD44 in ovarian cancer remains controversial [8–11]. 
On the basis of immunohistochemistry staining of our 
unique TMA, we found that the expression of CD44 
was more pronounced in the recurrent and metastatic 
ovarian cancer tissues, when compared with its primary 
counterparts. There was a significant correlation between 
CD44 expression and disease free survival and overall 
Figure 5: Inhibition of CD44 expression by transfection of CD44 esiRNA in ovarian cancer cell lines. Panel (A and B) 
western blot demonstrating knockdown of CD44 and relative expression of Pgp in drug resistant cell lines post transfection CD44 esiRNA 
48 hours. The western bolt was performed in triplicate. Panel (C and D) immunofluorescence photos for CD44 (red) and nuclei (blue) of 
ovarian cancer cell lines treated with CD44 esiRNA and non-specific siRNA. This assay was repeated twice.
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survival. Consequently, our investigations demonstrated 
that high expression of CD44 predicts an unfavorable 
prognosis in ovarian carcinoma.
Among the critical characteristics of an aggressive 
malignant ovarian cancer phenotype are rapid cell 
proliferation, migration, and invasion. CD44 plays an 
important role in communication of cell-matrix interactions, 
cell motility, matrix degradation, proliferation, and survival. 
Previous reports have found that suppressing CD44 by 
its specific siRNA dramatically decreases the migratory 
potentials and invasiveness of ovarian cancer cells [24–26]. 
We have similar findings when knocking down CD44 by 
efficient and specific esiRNA in malignant drug resistant 
ovarian cancer cell lines. More importantly, stable CD44 
knockdown ovarian cancer cell lines and their negative 
controls have been well established, characterized, and 
intensively studied in the current work. Those cell lines 
were cultured in 3-D environment, which can mimic in vivo 
growth conditions. When CD44 was stably knocked down 
by targeted shRNA, the formation of spheroids under 3-D 
culture and the growth speed were significantly suppressed. 
In recent in vivo reports, there was effective tumor shrinkage 
in xenograft models by suppressing CD44 mRNA and 
protein [24, 27]. It has been demonstrated that peritoneal 
cells produce several extracellular matrix molecules that 
interact with CD44 receptor, such as hyaluronic acid (HA, 
hyaluronan, a linear polymer of repeating disaccharide 
units [D-glucuronic acid (1-β-3) N-acetyl-D-glucosamine 
(1-β-4)]n), collagen, osteopontin (OPN), and L-selectin and 
E-selectin, etc [28–31]. The principal molecule among these 
is HA; when CD44 on the surface of ovarian cancer cells 
binds to HA on mesothelial cells, this combination may 
trigger peritoneal metastasis [32, 33]. A study focused on 
colon cancer has also demonstrated that CD44 expressed 
on the cell surface can facilitate binding endothelial P- or 
L-selectin and increase haematogenous spread of tumor 
[34]. Although the role CD44 expression plays in ovarian 
cancer recurrence, metastasis, and drug resistance is 
unknown, the results showing that knockdown of CD44 
inhibits tumor cell proliferation and migration/invasion 
provides evidence that CD44 may directly participate in 
ovarian cancer progression.
Tumor recurrence under common cytotoxic 
chemotherapy is one of the most challenging problems 
in cancer treatment, not limited to ovarian cancer. 
Nevertheless, the molecular mechanisms elucidating tumor 
recurrence and chemoresistance are widely investigated 
but still poorly understood. In this study, overexpression 
of CD44 was found in the tumor recurrence of xenograft 
mouse model undergoing paclitaxel treatment. The present 
work, to our knowledge, is the first evaluation of CD44 
expression during paclitaxel treatment in vivo. Moreover, 
the expression level of CD44 was also examined in 
paclitaxel-resistant cell lines. The expression of CD44 
was significantly higher in the paclitaxel-resistant cells 
lines than in the drug sensitive parental cell lines. Previous 
studies have shown that reducing the expression level of 
CD44 by siRNA increased sensitivity to doxorubicin in 
breast cancer [35]. Downregulation of CD44 by miR-
199a-3p significantly increased the chemosensitivity 
Figure 6: Transfection of CD44 esiRNA suppressed the migratory and invasion activity of ovarian cancer cell lines. Panel 
(A and C) relative migration distance of SKOV-3TR and OVCAR8TR at different time points (0 hour, 8 hours, 24 hours) when transfected 
with different concentrations of CD44 esiRNA and non-specific siRNA. The wound healing assay was conducted in duplicate. Panel 
(B and D) numbers of cell invasion through the Matrigel after 24 hours when transfected with different concentrations of CD44 esiRNA 
and non-specific siRNA. The matrigel invasion assay was repeated twice.
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of ovarian cancer cells to cisplatin, pacitaxel, and 
adriamycin [27]. In accordance with the previous studies, 
we demonstrated that stable suppression of CD44 by 
lentivirus-based CD44 shRNA increased sensitivity to 
paclitaxel. Overexpression of MDR1 protein Pgp acts 
as an energy-dependent drug efflux pump to pump out 
many structurally unrelated chemotherapeutic drugs. 
It has been recognized as one of the well characterized 
mechanism for resistant to drug, including paclitaxel 
[36, 37]. Importantly, either transient or stable knockdown 
of CD44 cannot induce the alteration of Pgp in drug resistant 
or sensitive phenotypes. Although the mechanism by which 
CD44 induces drug resistance and tumor recurrence is 
unknown, our findings indicate that this does not appear 
to be via MDR1-dependent mechanism. Hedgehog 
signaling pathway has been shown to be important in the 
maintenance of chemotherapy resistance in a subgroup of 
CD44+ gastric cancer cells [38]. Overexpression of CD44 
has also been shown to promote resistance to etoposide-
induced apoptosis by alteration of levels of caspase 9, 
caspase 3, Bcl-xl, and Bak, down-regulation of pRB, and 
phosphorylation of AKT in colon cancer [39]. Genetic loss 
of CD44 in murine chronic lymphocytic leukemia had a 
negative impact on the phosphoactivation of important 
antiapoptotic regulators, ERK1/2 and AKT kinases [40]. 
Another potential mechanism is that CD44 functions 
in drug resistance as an antiapoptotic factor through up-
regulation of Bcl-xL in breast cancer [41].
In conclusion, we demonstrate CD44 is significantly 
up-regulated during the progression of human ovarian 
cancer, including recurrence, metastasis, and acquisition of 
drug resistance. CD44 plays crucial roles in ovarian cancer 
cell growth, migration, and invasion. These results suggest 
that developing new strategies to target CD44 in ovarian 
cancer may prevent recurrence, metastasis, and drug 
resistance, and improve the clinical outcome of ovarian 
cancer patients.
MATERIALS AND METHODS
Ovarian cancer tissue microarray (TMA)
A total of 26 individual ovarian cancer patients 
during their treatment at Massachusetts General Hospital 
were recruited in this study. The archived, formalin-fixed, 
paraffin-embedded tumor specimens from patients were 
selected for construction of the human ovarian cancer 
TMA, which was generated by the Tissue Microarray Core 
at the Dana-Farber/Harvard Cancer Center. Each of these 
26 patients’ tumor tissue blocks were composed of: 1) a 
primary tumor, 2) a synchronous metastasis obtained at 
the time of the primary surgery, and 3) a metachronous 
recurrence from the same patient collected at the time 
of tumor recurrence after platinum- and taxane-based 
chemotherapy treatment. Haematoxylin and eosin-stained 
slides from each tissue block were read by a senior 
consultant pathologist, together with pathology reports 
to obtain representative triplicate 0.5-mm-diameter core 
biopsies of primary, metastasis, and recurrent ovarian 
cancer tumors (absence of necrosis, poorly differentiated 
tumor areas). Pathological identification of diagnosis 
and staging of all the patients was in accordance with 
World Health Organization criteria and the Federation 
International of Gynecology and Obstetrics (FIGO) 
guidelines on the management of ovarian cancer [42–44]. 
Other relevant clinical information was also collected, 
including ascites present at surgery, disease free survival 
(DFS) as the interval between date of diagnosis and date 
of recurrence, overall survival (OS) as the interval from 
date of surgery to death or to last follow-up (for censored 
events), as well as current patient status. The process of 
case collection was approved by the Institutional Review 
Board at Massachusetts General Hospital.
Immunohistochemistry
The expression level of CD44 was determined 
based on the Immunohistochemistry Protocol (Paraffin) 
from Cell Signaling Technology (Beverly, MA). Briefly, 
5-μm paraffin tissue section slides were baked at 60°C 
for 1 hour, deparaffinized in xylene for 10 minutes, and 
then transferred through graded ethanol for rehydration. 
Following the process of antigen retrieval, endogenous 
peroxidase activity was quenched by incubation in 3% 
hydrogen peroxide. After protein blocking with blocking 
solution (Cell Signaling Technology) for 1 hour at 
room temperature, primary antibody was applied at 4°C 
overnight in a humidified chamber. Each step preceded 
three Tris-buffered saline (TBS) rinses, and the bounded 
antibody on the array was detected by using SignalStain® 
Boost Detection Reagent (Cell Signaling Technology) and 
SignalStain® DAB (Cell Signaling Technology). Prior to 
imaging, the section was counterstained with hematoxylin 
QS (Vector Laboratories) and mounted with VectaMount 
AQ (Vector Laboratories) for long-term preservation. The 
expression of CD44 was evaluated by two scientists who 
had no knowledge of the clinical data and the other viewer’s 
score. The immunostaining intensity pattern of CD44 was 
assessed on a scale semiquantitatively as follows: 0, no 
staining; 1+, weak staining; 2+, moderate staining; and 3+, 
intense staining. Scoring was calculated from the mean of 
the two independently conducted assessments.
Tumor xenograft model and treatment
In order to determine the effect of chemotherapy 
treatment on CD44 expression in ovarian cancer in vivo, 
an ovarian cancer xenograft mouse model was established 
and paclitaxel treatment was subsequently carried out. 
Specifically, SKOV-3 cell suspension (2 × 106) was 
mixed with matrigel (BD Biosciences, San Jose, CA) in 
volume ratio 1: 1, and the mixture was injected into the 
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flanks of 4–6-week-old Crl:SHO-PrkdcSCIDHrhr nude 
female mice (Charles River Laboratories, Ann Arbor, 
MI) subcutaneously. Approval of the study protocol 
was obtained and supervised by Massachusetts General 
Hospital Subcommittee on Research Animal Care (SRAC). 
When the tumor volume of mice reached approximately 
150 mm3, the mice (six per group) were randomly assigned 
to control or treatment groups, and dosed with saline or 
different dosages of paclitaxel (10 mg/kg, 20 mg/kg, 
25 mg/kg, respectively) by tail vein injection. The treatment 
schedule was conducted twice a week until the tumor grew 
larger than 15 mm in diameter or exceeded 1000 mm3. 
The health of the mice was monitored daily during the 
treatment period. The animals were weighed and tumor 
size was measured by a caliper twice a week. At the end 
of the experiments, the animals were euthanized; tumors 
were harvested and stored at –80°C for protein extraction.
Cell lines and reagents
Ovarian cancer cell lines SKOV-3, OVCAR8, 
and multidrug resistance (MDR) ovarian cancer cell 
lines SKOV-3TR and OVCAR8TR used in this study 
were characterized previously [45–48]. All cells were 
cultured in RPMI 1640 (Life Technologies, Grand Island, 
NY) supplemented with 10% fetal bovine serum (FBS) 
and 1% penicillin/streptomycin (Life Technologies, 
Carlsbad, CA) at 37°C in atmosphere composed of 
5% CO
2
 and 95% air. Human non-specific siRNA and 
CD44 targeted endoribonuclease-prepared siRNA 
(esiRNA, Genebank Accession Number NM_001001391, 
5′-TTAAAGGGATTCCCATCATTGGAATCTTAT-3′) 
were purchased from Sigma-Aldrich (St. Louis, MO). 
esiRNAs are synthesized by in vitro transcription of a 
300–600 bp gene specific dsRNA, followed by enzymatic 
digestion using RNAses (i.e., RNase III). esiRNAs are 
pools of siRNAs that all target the same mRNA sequence 
with high specificity. This strategy eliminates the trial and 
error approach of identifying a useful synthetic siRNA and 
ensures minimal risk of off-target effects [49]. Therefore, 
we selected CD44 targeted esiRNA as transient transfection 
tool in this study. Lipofectamine® RNAiMAX was 
purchased from Life Technologies Corp. The monoclonal 
mouse anti-human CD44 antibody was obtained from Cell 
Signaling Technology, which was produced by immunizing 
BALB/c mice with stimulated human leukocytes and 
recognizes residues surrounding Ser210 of human CD44. 
The monoclonal rabbit anti-human Pgp antibody, which 
recognizes endogenous levels of total MDR1/ABCB1 
protein, was also obtained from Cell Signaling Technology.
Establishment of stable CD44 knockdown 
ovarian cancer cell line by CD44 shRNA
Further validation of CD44 knockdown 
phenotype in ovarian cell line was carried out with 
CD44 lentiviral shRNA (Sigma-Aldrich). The shRNA 
sequence targeting CD44 corresponded to coding regions 
(5′-CCGGATGGACTCCAGTCATAGTATACTCGAGTA 
TACTATGACTGGAGTCCATTTTTTG-3′) of the CD44 
gene. As compared with siRNA or esiRNA, which can 
transiently (usually between 24 to 96 hours) knockdown 
gene expression as described above, the advantage of 
using lentiviral shRNA is the ability to create a stable 
CD44 knockdown cell line. OVCAR8 expresses CD44 to 
some extent and is susceptible to the lentivirus-screening 
antibiotic puromycin. Hence, OVCAR8 was used to 
establish the stable CD44 knockdown ovarian cancer cell 
line in this study. Briefly, OVCAR8 cells were seeded 
(2 × 103 per well) in a 96-well microplate and incubated 
with CD44 shRNA lentivirus for 24 hours at 37°C in 
a humidified incubator in an atmosphere of 5% CO
2
. 
Untreated cells were used as blank control; a lentiviral 
empty vector and lentivirus-based non-specific shRNA 
were used as negative controls. Each lentiviral construct 
and control was plated in duplicate wells. Hexadimethrine 
bromide was added to enhance transduction efficacy. Fresh 
medium containing 2 μg/ml puromycin, which is lethal to 
most lentivirus-untransduced cells, was exchanged every 
3–4 days until resistant colonies were identified (Figure 3 
Panel A). The knockdown efficiency of CD44 shRNA was 
then confirmed by western blot when all cell lines grew 
vigorously. These cells lines were coined as OVCAR8CD44 
shRNA, OVCAR8Lentivirus only, and OVCAR8Non-specific shRNA 
according to the above-mentioned different treatments.
Determination of the CD44 knockdown effect 
on spheroid formation in 3-Dimensional (3-D) 
culture of ovarian cancer cells
Cell spheroid formation was performed following 
HDP1096 Perfecta3D® 96-Well Hanging Drop Plates 
Protocol (3D Biomatrix). Initially, due to the small 
volume of hanging drops, which makes them susceptible 
to evaporation and the variability in incubator conditions, 
pre-heated agarose solution was filled into the reservoirs 
of plate to better maintain the humidity condition 
of spheroid culture. Hanging drops were formed by 
pipetting 40 μL of cell suspension (2.5 × 105/ml) into 
each well, OVCAR8, OVCAR8Lentivirus only, OVCAR8Non-
specific shRNA, and OVCAR8CD44 shRNA, respectively. 10 μL of 
fresh medium was added back into the hanging drops 
slowly every other day to provide enough nutrients for 
cells and to prevent osmolality shift of the medium. 
The spheroids were harvested for further study from the 
bottom side of the plate by pipetting 100 μL Phosphate 
Buffer Solution (PBS) into each well gently without 
any destruction of the morphology of the spheroids. 
Finally, the spheroids were photographed on a Nikon 
Eclipse Ti-U inverted fluorescence microscope (Nikon 
Instruments, Inc NY, CA) after incubating with 1 μM 
Calcein AM (Life Technologies) for 15 min. The size of 
tumor spheroids was computed based on image analysis 
(by the software ImageJ).
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Cell viability analysis
Proliferation ability and cytotoxicity of anticancer 
drug paclitaxel in ovarian cancer cells were assessed by 
MTT (3(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium 
bromide) assay after CD44 was knocked down by CD44 
shRNA. Well-established cells (OVCAR8Lentivirus only, 
OVCAR8Non-specific shRNA, as well as OVCAR8CD44 shRNA) were 
seeded into 96-well microplate at the density of 1 × 103 
cells per well and exposed to different concentrations of 
paclitaxel which were obtained from the pharmacy at the 
Massachusetts General Hospital. After 7-day incubation 
with a series concentrations of paclitaxel, 20 μL MTT 
(Sigma-Aldrich) was added and then incubated for another 
4 hours at 37°C and 5% CO
2
 humidified atmosphere. 
Subsequently, the resulting intracellular formazan crystals 
was solubilized in acid-isopropanol. The absorbances were 
assessed on a SpectraMax Microplate® Spectrophotometer 
(Molecular Devices LLC, Sunnyvale, CA) at 490 nm, and 
normalized to the value of untreated cells.
Western blot
Protein lysates of the cells and tissues were 
extracted with 1 × RIPA lysis buffer (Upstate 
Biotechnology, Charlottesville, VA) plus complete 
protease inhibitor cocktail tablets (Roche Applied 
Science, IN, USA). The protein concentrations were 
evaluated using Protein Assay Reagents (Bio-Rad, 
Hercules, USA) and a SPECTRAmax Microplate 
Spectrophotometer from Molecular Devices (Sunnyvale). 
Equal amounts of proteins were separated by NuPAGE® 
4–12% Bis-Tris Gel (Life Technologies), transferred onto 
nitrocellulose membrane (Bio-Rad), and incubated with 
specific primary antibodies (CD44 at 1 : 1000 dilutions; 
Pgp at 1 : 1000 dilutions; β-Actin at 1 : 2000 dilutions) at 
4°C overnight. The membranes were further probed with 
respective secondary antibodies (LI-COR Bioscences, 
Lincoln, NE), and scanned by Odyssey® CLx equipment 
(LI-COR Bioscences) to detect the bands. Furthermore, 
the density of the bands was quantified by Odyssey 
software 3.0 (LI-COR Bioscences).
Immunofluorescence
Immunofluorescence assay was utilized for 
visualizing the post transfection expression levels of CD44 
in ovarian cancer cells. Firstly, the 48-hour post transfection 
cells were incubated in 4% paraformaldehyde, fixed in ice-
cold methanol, and blocked with 1% bovine serum albumin 
(BSA). Then, immunostaining was performed using the 
CD44 antibody, Alexa Fluor 594 (Red) conjugated goat 
anti-mouse antibody (Life Technologies), and 1 μg/ml 
Hoechst 33342 (Life Technologies) for counterstaining of 
nuclei. Finally, the cells were photographed on a Nikon 
Eclipse Ti-U fluorescence microscope (Nikon Instruments, 
Inc NY, CA) equipped with a SPOT RTTM digital camera. 
Red color represented CD44 protein and blue color 
represented cell nuclei.
Wound healing assay
The effect of CD44 knockdown in ovarian cancer 
cells on migration was evaluated by wound healing 
assay. In brief, 2 × 105 cells were seeded onto a 12-well 
plate, and transfected with CD44 esiRNA or non-specific 
siRNA. When the cells reached 80–100% confluence, 
three parallel lines with similar width were then created 
in each well using sterile 200 μL pipette tips and rinsed to 
clear cell debris and suspension cells. Fresh regular RPMI 
1640 medium was added and the cells were allowed to 
close the wound for 24 hours. Three images were captured 
per well at different time points after wounding (0, 8 and 
24 hours) to monitor the repair process by a microscope 
(Nikon) at 100× magnification. The width of the wound 
was measured at 10 sites in each image. The cell migration 
distance was calculated by subtracting the wound width at 
each time point from the wound width at the 0 hour.
Matrigel invasion assay
Matrigel invasion assay examined the alteration of 
cell invasion activity using a BD BioCoatTM MatrigelTM 
Invasion Chamber (Becton-Dickinson, MA) following the 
manufacturer’s recommendations. Specifically, 5 × 104 
cells were added into the upper chamber of each well in 
FBS-free and antibiotics-free medium, and transfected 
with CD44 esiRNA or non-specific siRNA in the same 
transfection protocol as mentioned above, while the 
bottom chambers were filled with 500 μL medium with 
10% FBS without antibiotics. After a 48-hour incubation 
period, the non-invading cells were carefully scrubbed 
from the upper surface of the membrane with a cotton 
swab. Following the processes of fixation in 100% 
methanol and staining in hematoxylin, the invading cells 
were counted in three images of each membrane under a 
microscope using a 200× objective.
Statistic analysis
The data were analyzed using Prism 5.0 software 
(Graph Pad Software Inc., San Diego, CA), and expressed 
as mean ± SEM. Statistical significance was assessed using 
independent two-tailed Student t-tests for independent 
data. Disease free survival and overall survival were 
analyzed using Kaplan-Meier survival curves with Gehan-
Breslow-Wilcoxon test for significance. Differences of 
P < 0.05 were considered significant for all statistical tests.
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